China Releases Interpretations Of Criminal Activities Associated With Counterfeit Drugs
This article was originally published in PharmAsia News
At a recent press conference by China's State Council Information Office, top executives from the People's Supreme Court and Procuratorate introduced the background, procedures and main content on the interpretation draft of the law against counterfeit and inferior medicines. Officially enforced on May 27, the legal application seeks to improve the criteria for determining the crimes of: production and sale of counterfeit drugs that are seriously harmful to health; damaging consequences for physical injuries caused by fake medicines; healthcare institutions that knowingly apply or sell counterfeit or inferior drugs, and their responsibilities according to criminal investigation; and those who facilitate illegal sales by providing mailing and advertising services. (Click here for more - Chinese Language)
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.